A Comparative Single Blind Clinical Study on the Effect of Alvogyl, Eugenol, and Nigella Sativa (Black Seed Oil) for Alveolar Osteitis.

NCT06823544 | Not Yet Recruiting Phase 2 DMC

• 1 other identifier: Bilalkhan321@gmail.com
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

Dry socket the unscientific term also known as alveolar or fibrinolytic osteitis is the most common postoperative complication following tooth extraction. Treatment of Alveolar osteitis can be either pharmacological on non-pharmacological. Management can be by irrigation, surgical intervention and placement of medicated dressing such as topical anti-bacterial, topical anesthetics and obtundants or combination of these three.this study aims to find the best and effective treatment for dry socket comparing Alveogyl, Eugenol and Black seed oil at this institution.

Conditions

Alveolar Osteitis

Keywords

Alveolar Osteitis; Alvogyl; Black seed oil; Eugenol; Extraction socket

Outcome Measures

Primary Outcomes (2)

• Visual Analogue Scale

  pain will assessed using Visual Analogue scale on day 2, 6, 10 and 14th after the start of treatment. Visual Analogue Score measurement will be scale based from 1 to 10 score. Where 1-3 is mild, 3-7 is moderate and 7-10 will be scored as severe pain.

  14 days

• Periodontal Probe

  alveolar osteitis affected extraction socket will be observed for the resolution of inflammation and healing will be assessed on day 2, 6, 10 and 14 by clinical examination with periodontal Probe. Periodontal depth will be measured in mm, by using the periodontal probe where the depth of 1 to 3 mm is considered well healed socket, 4-6 mm indicates moderately inflamed, 7 mm and above is considered severely inflammed .

  14 days

Study Arms (3)

Alvogyl

EXPERIMENTAL

this group will be assigned Alvogyl as treatment drug

Drug: Alvogyl

Eugenol

EXPERIMENTAL

this group will be assigned Eugenol as treatment drug

Drug: Eugenol

Black Seed Oil

EXPERIMENTAL

this group will be assigned Nigella Sativa as treatment drug

Drug: Nigella Sativa Oil

Interventions

Alvogyl DRUG

this is standard treatment drug

Alvogyl

Eugenol DRUG

this not standard drug for the treatment of Alveolar Osteitis but an antiseptic agent

Eugenol

Nigella Sativa Oil DRUG

it not standard medicine for Alveolar Osteitis. it is a herbal medicine

Black Seed Oil

Eligibility Criteria

• Age: 16 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients over the age of 16, from both genders, who had their teeth extracted and were clinically diagnosed with dry socket.
• Absence of systematic disease.

You may not qualify if:

• SMOKER
• ALCOHOLIC
• Patients under the age of 16 years and over the age of 70 years
• Patient with various bone diseases including osteoporosis.
• Patients who had a history of taking oral or intravenous bisphosphonates.
• Patients with a history of radiotherapy to the head and neck and jawbones.

Sponsors & Collaborators

• HITEC-Institute of Medical Sciences: lead

Study Sites (1)

Department of Oral & Maxillofacial Surgery-Dental College HITEC-IMS TAXILA CANTT

Taxila Cantt, Punjab Province, 47070, Pakistan

Location

MeSH Terms

Conditions

Dry Socket

Interventions

butyl aminobenzoate, eugenol, iodoform, spearmint oil drug combinations; Eugenol; Nigella sativa oil

Condition Hierarchy (Ancestors)

Mouth Diseases; Stomatognathic Diseases

Intervention Hierarchy (Ancestors)

Caffeic Acids; Cinnamates; Acids, Carbocyclic; Carboxylic Acids; Organic Chemicals; Allylbenzene Derivatives; Allyl Compounds; Alkenes; Hydrocarbons, Acyclic; Hydrocarbons; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic

Study Officials

• MAIMOONA Siddiq Dr, BDS-FCPS

  Department of Oral & Maxillofacial Surgery-Dental College HITEC-IMS

  STUDY DIRECTOR

• Muhammad Bilal Dr, BDS

  Department of Oral & Maxillofacial Surgery-Dental College HITEC-IMS

  PRINCIPAL INVESTIGATOR

Central Study Contacts

MUHAMMAD BILAL

CONTACT

+92519315698; Bilalkhan321@gmail.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: January 19, 2025
• First Posted: February 12, 2025
• Study Start: February 1, 2025
• Primary Completion: July 31, 2025
• Study Completion: August 31, 2025
• Last Updated: February 12, 2025

Record last verified: 2025-02

Data Sharing

• IPD Sharing: Will not share

Locations

PA (1)